Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00362895 · ClinicalTrials.gov registry record · Phase 3
A Bioequivalence Study of Tobradex AF
A Phase 3 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 995
- Enrollment target
NCT00362895 is a Phase 3 study that has completed, run by Alcon Research. The registered enrollment target is 995 participants.
The verdict
NCT00362895, a Phase 3 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 995 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the amount of study medication that moves from the front of the eye into the fluid at the front of the inside of the eye.
Interventions
- DRUG Tobramycin 0.3% / Dexamethasone 0.033% ophthalmic suspension
- DRUG Tobramycin 0.3% / Dexamethasone 0.1% ophthalmic suspension (TOBRADEX)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 995 participants |
| Start Date | 2006-04 |
| Est. Completion | 2006-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00362895
The ClinicalTrials.gov registry entry for NCT00362895 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 995 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tobramycin 0.3% / Dexamethasone 0.033% ophthalmic suspension is the first listed.
NCT00362895 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00362895 about?
NCT00362895 is a clinical study titled "A Bioequivalence Study of Tobradex AF". The purpose of the study is to determine the amount of study medication that moves from the front of the eye into the fluid at the front of the inside of the eye.
What is the current status of trial NCT00362895?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 995 participants. The study started on 2006-04. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00362895?
The interventions under investigation include: Tobramycin 0.3% / Dexamethasone 0.033% ophthalmic suspension (DRUG), Tobramycin 0.3% / Dexamethasone 0.1% ophthalmic suspension (TOBRADEX) (DRUG).
Who is sponsoring clinical trial NCT00362895?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.